 
        
        
        
                货号:A105695
                
                同义名:
                    
                        
                            
                                Diclofenac Sodium; GP 45840
                            
                        
                    
                
                
                
                    
                     
                
            
Diclofenac Sodium Salt是一种非选择性环氧化酶(COX)抑制剂。常用作非类固醇抗炎药(NSAID),用于缓解疼痛和减少炎症。
 HazMat Fee +
 HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) | 
| Excepted Quantity | USD 0.00 | 
| Limited Quantity | USD 15-60 | 
| Inaccessible (Haz class 6.1), Domestic | USD 80+ | 
| Inaccessible (Haz class 6.1), International | USD 150+ | 
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ | 
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ | 
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | COX ↓ ↑ | COX-1 ↓ ↑ | COX-2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Piroxicam | ✔ | 98% | |||||||||||||||||
| Salicylic acid | ✔ | 98% | |||||||||||||||||
| Phenacetin | ✔ | 98% | |||||||||||||||||
| Etodolac | ✔ | 99% | |||||||||||||||||
| Flunixin meglumine | ✔ | 98% | |||||||||||||||||
| Ibuprofen L-lysine | ✔ | 98% | |||||||||||||||||
| Nabumetone | ✔ | 98% | |||||||||||||||||
| Acemetacin | ✔ | 98% | |||||||||||||||||
| Diflunisal | ✔ | 98% | |||||||||||||||||
| Pranoprofen | ✔ | 98% | |||||||||||||||||
| Ampiroxicam | ✔ | 98% | |||||||||||||||||
| Meloxicam | ✔ | 98% | |||||||||||||||||
| Sulindac | ✔ | 98% | |||||||||||||||||
| Ketoprofen | ✔ | 98% | |||||||||||||||||
| Mefenamic Acid | ✔ | 95% | |||||||||||||||||
| Bromfenac sodium | ✔ | 98% | |||||||||||||||||
| Oxaprozin | ✔ | 99% | |||||||||||||||||
| Aspirin | ✔ | 99% | |||||||||||||||||
| Nepafenac | ✔ | 98% | |||||||||||||||||
| Zaltoprofen | ✔ | 99% | |||||||||||||||||
| Salicin | ✔ | 98% | |||||||||||||||||
| Suprofen | ✔ | 99%+ | |||||||||||||||||
| Xanthohumol | ✔ | 99% | |||||||||||||||||
| Parecoxib | ✔ | 98% | |||||||||||||||||
| Tolfenamic Acid | +++ COX-2, IC50: 0.2 μM | 98% | |||||||||||||||||
| Etoricoxib | ✔ | 99% | |||||||||||||||||
| Niflumic Acid | ✔ | 98% | |||||||||||||||||
| Valdecoxib | ++++ COX-2, IC50: 5 nM | 99+% | |||||||||||||||||
| Ibuprofen | + COX-1, IC50: 13 μM | + COX-2, IC50: 370 μM | 98% | ||||||||||||||||
| Indomethacin | ++ COX1, IC50: 0.28 μM | + COX-2, IC50: 14 μM | 97% | ||||||||||||||||
| Lornoxicam | ++++ COX-1, IC50: 5 nM | ++++ COX-2, IC50: 8 nM | 98% | ||||||||||||||||
| Meclofenamic acid sodium | ++++ COX-1, IC50: 40 nM | +++ COX-2, IC50: 50 nM | 99% | ||||||||||||||||
| Asaraldehyde | ✔ | 98% | |||||||||||||||||
| Naproxen | + COX-1, IC50: 8.7 μM | + COX-2, IC50: 5.2 μM | 98% | ||||||||||||||||
| Diclofenac Sodium Salt | +++ COX-1, IC50: 60 nM | +++ COX-2, IC50: 200 nM | 98% | ||||||||||||||||
| NS-398 | ++ COX-2, IC50: 3.8 μM | 95% | |||||||||||||||||
| Amfenac Sodium Hydrate | ++ COX-1, IC50: 250 nM | +++ COX-2, IC50: 150 nM | 98%+ | ||||||||||||||||
| Nimesulide | + COX-2, IC50: 26 μM | 98% | |||||||||||||||||
| Lumiracoxib | ++ COX-1, Ki: 3 μM | +++ COX-2, Ki: 60 nM | 98% | ||||||||||||||||
| Rutaecarpine | ✔ | 95% | |||||||||||||||||
| Celecoxib | ++++ COX-2, IC50: 40 nM | 98% | |||||||||||||||||
| Carprofen | ++++ canine COX2, IC50: 30 nM | 98% | |||||||||||||||||
| Ketorolac | ++ COX-1 (human), IC50: 1.23 μM | ++ COX-2 (human), IC50: 3.50 μM | 98% | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 | 
 | 
| 描述 | Diclofenac Sodium (GP 45840) is a potent, nonselective anti-inflammatory agent that functions as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells[1]. Diclofenac Sodium triggers apoptosis in neural stem cells (NSCs) by activating the caspase cascade[3]. | 
| Concentration | Treated Time | Description | References | |
| MRSE ATCC 35984 | 125 µg mL−1 | 24 hours | Inhibits MRSE growth | Adv Sci (Weinh). 2021 May 3;8(13):2100681. | 
| MSSA ATCC 25923 | 125 µg mL−1 | 24 hours | Inhibits MSSA growth | Adv Sci (Weinh). 2021 May 3;8(13):2100681. | 
| Mouse adult tail-tip fibroblasts (TTFs) | 10 μM | 1 week | Diclofenac significantly enhanced cardiac reprogramming efficiency in adult TTFs by about 3 fold | Nat Commun. 2019 Feb 20;10(1):674. | 
| Mouse postnatal tail-tip fibroblasts (TTFs) | 10 μM | 1 week | Diclofenac significantly enhanced cardiac reprogramming efficiency in postnatal TTFs by 3-4 fold | Nat Commun. 2019 Feb 20;10(1):674. | 
| Mouse embryonic fibroblasts (MEFs) | 10 μM | 1 week | Diclofenac did not substantially promote cardiac reprogramming in MEFs | Nat Commun. 2019 Feb 20;10(1):674. | 
| Mouse primary hepatocytes | 300 µM | 24 hours | To evaluate the effect of diclofenac on lipid accumulation in mouse primary hepatocytes, results showed that diclofenac significantly increased neutral lipid accumulation and triglyceride levels. | Theranostics. 2022 Feb 21;12(5):2351-2369. | 
| HepG2 cells | 300 µM | 24 hours | To evaluate the effect of diclofenac on lipid accumulation in hepatocytes, results showed that diclofenac significantly increased neutral lipid accumulation. | Theranostics. 2022 Feb 21;12(5):2351-2369. | 
| MRSA ATCC 43300 | 125 µg mL−1 | 24 hours | Inhibits MRSA growth and does not easily induce drug-resistant mutations | Adv Sci (Weinh). 2021 May 3;8(13):2100681. | 
| Intestinal microsomes | 100 μmol/L | 30 minutes | To evaluate the metabolic rate of diclofenac in intestinal microsomes, results showed that the formation rates of 4'-OH-DCF and 5-OH-DCF were reduced by 58% and 64%, respectively, in DSS-induced colitis mice. | Acta Pharm Sin B. 2020 Jan;10(1):123-135. | 
| Hepatic microsomes | 100 μmol/L | 30 minutes | To evaluate the metabolic rate of diclofenac in hepatic microsomes, results showed that the formation rates of 4'-OH-DCF (CYP2C metabolite) and 5-OH-DCF (CYP3A metabolite) were reduced by 23% and 27%, respectively, in DSS-induced colitis mice. | Acta Pharm Sin B. 2020 Jan;10(1):123-135. | 
| Fibroblast-like synoviocytes (FLS) | 147.1 μmol/L (DC) and 73.6 μmol/L (LND) | 24 hours | To verify the synergistic inhibitory effect of diclofenac (DC) and lonidamine (LND) on the survival, proliferation, and activation of FLS. Results showed that the combination treatment significantly reduced FLS viability and induced higher apoptosis rates (31.6%). | Acta Pharm Sin B. 2025 Jan;15(1):542-556. | 
| Fadu cells | 10ug/g | every other day | To investigate the effect of diclofenac on LAMP2A expression, results showed that diclofenac significantly decreased LAMP2A expression levels. | Theranostics. 2025 Feb 18;15(7):3207-3222. | 
| Administration | Dosage | Frequency | Description | References | ||
| Rats | Carrageenan-induced rat paw edema model | Oral | 10 mg/kg | Single dose | Evaluation of anti-inflammatory activity, diclofenac sodium showed 81.62% inhibition. | Acta Pharm Sin B. 2017 Mar;7(2):230-240 | 
| C57BL/6 mice | Osteoarthritis pain model | Oral | 10 mg/kg | Daily for 4 weeks | To evaluate the analgesic effect of diclofenac on mechanical joint loading-induced osteoarthritis pain. Results showed that diclofenac significantly alleviated mechanical hypersensitivity and improved weight distribution after 2 weeks of treatment. | Arthritis Rheumatol. 2019 Jul;71(7):1078-1088 | 
| C57BL/6 mice | Hepatic steatosis model | Intraperitoneal injection | 100 mg/kg | Every 12 hours for 24 hours | To evaluate the effect of diclofenac on hepatic lipid accumulation in mice, results showed that diclofenac significantly increased hepatic lipid accumulation and triglyceride levels. | Theranostics. 2022 Feb 21;12(5):2351-2369. | 
| C57BL/6 mice | Head and neck squamous cell carcinoma model | Intraperitoneal injection | 10 μg/g | Every other day for 10 days | To investigate the effect of diclofenac combined with PD-1 monoclonal antibody treatment, results showed that the combination treatment significantly inhibited tumor growth and enhanced CD8+ T cell infiltration. | Theranostics. 2025 Feb 18;15(7):3207-3222. | 
| CD1 ICR mice | Skin and soft tissue infection model | Subcutaneous injection | 80 mg/kg | Every 24 hours for 7 days | Combination with oxacillin significantly alleviates MRSA infection | Adv Sci (Weinh). 2021 May 3;8(13):2100681. | 
| Nude mice | 11q-deleted neuroblastoma xenograft model | Drinking water | 250 mg/L | Nine consecutive days | To assess the effect of COX inhibition on tumor growth in an 11q-deleted neuroblastoma model, results showed diclofenac treatment significantly reduced tumor growth and PGE2 levels. | Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8070-5 | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 3.14mL 0.63mL 0.31mL | 15.72mL 3.14mL 1.57mL | 31.43mL 6.29mL 3.14mL | |
| CAS号 | 15307-79-6 | 
| 分子式 | C14H10Cl2NNaO2 | 
| 分子量 | 318.13 | 
| SMILES Code | O=C([O-])CC1=CC=CC=C1NC2=C(Cl)C=CC=C2Cl.[Na+] | 
| MDL No. | MFCD00082251 | 
| 别名 | Diclofenac Sodium; GP 45840; Diclofenac(sodium salt); Diclofenac(Sodium) | 
| 运输 | 蓝冰 | 
| InChI Key | KPHWPUGNDIVLNH-UHFFFAOYSA-M | 
| Pubchem ID | 5018304 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, room temperature | 
| 溶解方案 | H2O: 10 mg/mL(31.43 mM),配合低频超声,并水浴加热至45℃助溶 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1